Profiles of Liver Function Tests Among Type 2 Diabetic Patients who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospital.
No Thumbnail Available
Date
2015-11
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Ababa University
Abstract
Background: - Diabetes Mellitus (DM) is a group of metabolic diseases characterized by
hyperglycemia with disturbances of carbohydrates, fat and protein metabolism resulting from
insufficient insulin secretion, defects in insulin secretion, insulin action, or both. Individuals with
type 2 diabetes have a higher incidence of liver function abnormalities. In this study we assess liver
function tests in patients with type 2 diabetes mellitus who are receiving different anti- diabetic drugs
and we examine factors associated with these biochemical changes.
Objective: - To investigate profile of liver function tests among type 2 diabetic patients who are
receiving different anti-diabetic drugs attending Tikur Anbessa Specialized Hospital.
Methods: - Hospital based cross-sectional study was conducted on 70 type 2 diabetic patients who
are receiving different anti-diabetic drugs and 35 type 2 diabetic patients who do not receive any
medication were recruited for this study. The blood was taken at the fasting period and liver
enzymes, total protein (TP), albumin (AL), total bilirubin (TB), fasting blood sugar (FBS), lipid
profiles and body mass index (BMI) were carried out in all patients and control group following the
standard procedures.
Results: Mean values of alkaline phosphatase (ALP), albumin (AL), TP and FBS were significantly
higher in type 2 diabetic patients receiving different anti-diabetic drugs than in control group. In
contrast, mean value of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
among study group were lower than control group. Mean values of TC and LDL were lower in study
group than in the control group. The mean value differences between the study group and control of
TB, TG and HDL were statistically not significant. There are no significant differences of liver
enzymes, TP, AL, TB, and lipid profiles in different patients who were on different anti-diabetic
drugs. But mean value of liver enzymes and lipid profiles were slightly lowered in patients receiving
mono therapy of insulin and metformin than insulin plus metformin, whereas BMI and FBS were
lowered in their combination therapy receiving group. Similarly mean value of FBS, ALT, TC, HDL,
LDL and lipid profiles were lowered in patients receiving mono therapy of glibenclamide and
metformin than glibenclamide plus metformin combination therapy receiving group, while BMI and
TB were increased in patients receiving mono therapy of metformin and glibenclamide.
Conclusion: The anti-diabetic drugs were found to have an effect in lowering liver enzymes and
lipid profiles in type 2 diabetic patients. The different biochemical parameters tested were more or
less similar in different groups of individuals who were on different anti-diabetic drugs of mono
therapy or combination therapy.
Keywords: - LFT; Alkaline phosphatase; Lipid profile; Aminotransferases (ALT & AST)
Description
Keywords
LFT; Alkaline phosphatase; Lipid profile; Aminotransferases (ALT & AST)